Research · Sep 3, 2026
NAUT: FY25 Deep Dive
Nautilus Biotechnology FY25 at $0M. NI $-59M; EPS $-0.47. Proteomics — Pre-revenue.
NAUT
Nautilus Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.90
−1.70%Research · Aug 25, 2026
Plasma Proteomics Shifts From Plex Count to Cross-Platform Accuracy
Independent cross-platform data now ranks plasma proteomics platforms: Seer cites 13.5% of its targets unlikely to concur, against 39% and over 45% for rivals.